A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Clinical trial NCT04853576 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04853576
Sponsor: Editas Medicine, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease Hemoglobinopathies

Start date: 2021-05-04
Primary completion: 2025-08-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.